Update Shows Long-Term Survival Benefit with Abemaciclib Plus Fulvestrant in HR-positive, HER2-negative Advanced Breast Cancer
Findings at 4-year follow-up in East Asian patients with advanced HR-positive, HER2-negative breast cancer are consistent with those in the overall MONARCH 2 study population